Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Burkitt Lymphoma 23Multiple Myeloma 21Lymphoma, Large B-Cell, Diffuse 21Leukemia, Myeloid, Acute 18Lymphoma, Non-Hodgkin 16Myelodysplastic Syndromes 15Lymphoma, B-Cell 14Lymphoma 14Recurrence 11Ovarian Neoplasms 11Lymphoma, Follicular 11Hodgkin Disease 11Triple Negative Breast Neoplasms 10Neoplasms 9Lymphoma, Mantle-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Breast Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Pancreatic Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Hematologic Neoplasms 7Sarcoma 6Osteosarcoma 6Leukemia, Myelomonocytic, Chronic 6Colorectal Neoplasms 6Lymphoma, B-Cell, Marginal Zone 5Leukemia, Biphenotypic, Acute 5Graft vs Host Disease 5

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating × Cyclophosphamide × 30 days × Clear all
NCT07526493 2026-05-12

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Tongji Hospital

Phase 1 Recruiting
6 enrolled

Multiple Sclerosis, Myasthenia Gravis, Myositis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡